Uses of Gemcitabine PCH 200mg

Gemcitabine PCH 200mg is indicated for the treatment of patients with non-small cell lung cancer, patients with metastatic breast tumors, bladder cancer patients... To better understand the use Gemcitabine PCH 200mg, patients can refer to the article below.

Gemcitabine PCH 200 mg has the main active ingredient Gemcitabine (used in the form of Gemcitabine hydrochloride) with the content of 200mg and the excipients are just enough for 1 tablet. The drug is prepared in the form of lyophilized powder for solution for injection, packing specification is 1 vial.

2.1. The effect of the drug Gemcitabine PCH 200mg Gemcitabine an anti-metabolite. After entering the body, Gemcitabine is converted to Gemcitabine diphosphate and Gemcitabine triphosphate which are active. Both substances work by the mechanism of thymidine nucleotide incorporation into the DNA strand, preventing DNA synthesis from developing normally.
2.2. Indications of Gemcitabine PCH 200mg Gemcitabine PCH 200mg is indicated for use in the following cases:
Patients with locally advanced or metastatic non-small cell lung cancer. Patients with adenocarcinoma, metastatic or locally advanced. Patients with pancreatic cancer resistant to 5-FU. Other therapeutic effects in prostate, ovarian, and breast cancers. Some patients have an effective treatment for advanced bladder and kidney cancer. 2.3. Contraindications to Gemcitabine PCH 200mg Absolutely patients should not use Gemcitabine when they are allergic to Gemcitabine ingredients or are sensitive to one of the ingredients in the drug.

3.1 Dosage of Gemcitabine PCH 200mg The recommended dose of Gemcitabine PCH 200mg is an intravenous infusion of 1000mg/m2 of skin area over 30 minutes. In some cases, it is possible to combine with Cisplatin to increase the effectiveness of treatment with prescribed regimens and with an appropriate dose according to each disease condition. The duration of drug use is adjusted depending on the disease condition and the purpose of the treatment course. Dosage may be reduced based on assessment of toxicity in the patient. 3.2. How to use Gemcitabine PCH 200mg Gemcitabine PCH 200mg is prepared in the form of lyophilized powder for intravenous infusion, so patients use the drug by intravenous infusion after mixing. The reconstituted Gemcitabine solution should be kept at room temperature (15-30 degrees Celsius) and should be used within 24 hours. The amount of medicine should be thrown away if it is not used up. The reconstituted solution should not be refrigerated as crystallization may occur. The drug should be observed before administering to the patient if there is a change in quality or color.

Symptoms of Gemcitabine PCH 200mg overdose include:
Severe rash. Itching, pain, burning in the hands or feet. Abnormal bleeding. Fever, sore throat, or other symptoms of infection. There is no antidote to treat Gemcitabine overdose. If symptoms of overdose are detected, the patient's blood cell count should be monitored. At the same time, it is necessary to take measures to support symptoms for patients when necessary.

On patients being treated with Gemcitabine PCH 200mg, there may be some unwanted side effects as follows: Nausea and vomiting, itching, allergies, skin rash, bone marrow depression, liver enzyme disorders, peeling skin flakes...
The side effects listed above are not exhaustive, in addition you may experience other side effects. Immediately notify your doctor or pharmacist when you see any unusual symptoms while taking the drug for advice and guidance.

Gemcitabine PCH 200mg can interact with some other drugs that can cause toxicity, increase side effects, reduce or lose activity.
Patients need to inform about the drugs, functional foods, vitamins being used, for advice and advice on using drugs more effectively and appropriately. Some drugs that interact with Gemcitabine PCH 200mg should be noted when used simultaneously: Bleomycin, Phenprocoumon, Warfarin, Coumarin.

Care should be taken when using the drug in patients with marrow failure or impaired liver and kidney function. During treatment with Gemcitabine PCH 200mg, it is necessary to have paraclinical testing facilities to conveniently monitor the patient's condition. Gemcitabine PCH 200mg does not seriously affect the process of driving vehicles and operating machinery and equipment. This drug should not be used in pregnant women and nursing mothers, because the drug may increase toxicity to the fetus and nursing baby. Tell your doctor if you have certain medical conditions such as chickenpox, Herpes zoster, infection, kidney disease, serious liver disease. The dose should be reduced or the patient discontinued if signs of drug toxicity are detected. Periodically check the patient's liver and kidney function such as transaminases and serum creatinine. Caution should be exercised when initiating Gemcitabine PCH 200 mg in patients with bone marrow failure. The above is important information about Gemcitabine PCH 200mg. If there are any problems that need further advice during use, patients can directly contact the prescribing doctor for advice.